No abstract

No abstract

: VANET is an application used for the intelligent transportation system which improves traffic safety as well as its efficiency. We have reviewed the patents related to vehicular Ad-Hoc Network and their issue. To avoid road accidents a lot of information we need in advance. This paper has developed a framework which minimizes the possibilities of the black hole attack in VANET. According to us, there are two possible solutions for this purpose. The first is to see alternative routes for the same destination. The second compromises of exploiting the packet header's packet sequence number which is always included in each packet header. The second procedure is able to verify that 72% to 96% of route which is discovered depends on pause time t which is the minimum time for delay in the packet transition in the network when AODV routing protocol is used for packet transitions. The framework is analyzed for the possible attacks by the Black Hole, and Gray Hole attacks and also effects of the attacks are recorded and studied by practically using it. A secured VANET is essential for the future of the network. Currently acquiring this network will boost the possibility of VANET to develop and reduce the time of its implementation in the real world scenarios. In this work it is concluded that both attacks can be implemented and detected over the network apart from of the fact that both attacks are categories differently.

Background: A simple and sensitive quantitation analytical technique by liquid chromatography–tandem mass spectrometry (LC-MS/MS) is essential for fedratinib in biological media with kinetic study in healthy rabbits. Objective: The main objectives of the present research work are to LC-MS/MS method development and validate procedure for the quantitation of fedratinib and its application to kinetic study in rabbits. Methods: Separation of processed samples were employed on zorbax SB C18 column (50mm×4.6 mm) 3.5µm with a movable phase of methanol, acetonitrile and 0.1% formic acid in the ratio of 30:60:10. The movable phase was monitored through column at 0.8 ml/min flow rate. The drug and ibrutinib internal standard (IS) were evaluated by monitoring the transitions of m/z -525.260/57.07 and 441.2/55.01 for fedratinib and IS respectively in multiple reaction monitoring mode. Results: The linear equation and coefficient of correlation (R2) results were y =0.00348x+0.00245 and 0.9984 respectively. Intra and inter-day precision %RSD findings of the developed technique were found in the range of 2.4 – 5.3% for the quality control (QC)-samples (252.56, 1804.0 and 2706 ng/ml). The proposed method was subjected for pharmacokinetic study in healthy rabbits and from the kinetic study, fedratinib was shown mean AUClast was 13190±18.1 hr*ng/ml and Cmax was found to be 3550±4.31 ng/ml in healthy rabbits. Conclusion: The validated method can be applicable for the pharmacokinetic and toxicokinetic studies in the clinical and forensic analysis of fedratinib in different kinds of biological matrices successfully.